BioMed Research International / 2014 / Article / Tab 2

Research Article

Antimicrobial and Controlled Release Studies of a Novel Nystatin Conjugated Iron Oxide Nanocomposite

Table 2

Percentage inhibition of nystatin chitosan magnetic nanocomposite against different microorganisms.

SampleConcentrationPercentage inhibition (Mean ± SEM)
Staphylococccus aureus Pseudomonas aeruginosa Escherichia coli Candida albicans

Nys-CS-MNP1 mg−10.236 ± 1.82199.014 ± 0.08125.771 ± 0.49893.750 ± 0.125
Nys-CS-MNP2 mg1.312 ± 0.00099.085 ± 0.00035.075 ± 0.43199.957 ± 0.025
CS1 mg−4.987 ± 0.00023.994 ± 0.81432.313 ± 0.43111.638 ± 1.246
CS2 mg−7.087 ± 1.82122.535 ± 4.07128.761 ± 0.43114.828 ± 0.000
MNPs1 mg0.787 ± 0.910−19.718 ± 0.81425.373 ± 4.31413.362 ± 0.249
MNPs2 mg−2.887 ± 0.000−4.676 ± 1.88926.866 ± 0.00013.793 ± 12.458
CS-MNP1 mg2.887 ± 0.000−7.042 ± 0.81416.418 ± 4.31414.828 ± 0.000
CS-MNP2 mg22.835 ± 0.910 1.268 ± 0.08124.627 ± 4.31414.267 ± 0.000

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.